Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Kyowa Kirin Co., Ltd.    4151   JP3256000005

KYOWA KIRIN CO., LTD.

(4151)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
10/23/2020 10/26/2020 10/27/2020 10/28/2020 10/29/2020 Date
2606 2619 2623 2671 2651 Last
471000 345500 504300 620100 833200 Volume
-0.72% +0.50% +0.15% +1.83% -0.75% Change
Financials
Sales 2020 322 B 3 073 M 3 073 M
Net income 2020 48 219 M 461 M 461 M
Net cash position 2020 191 B 1 829 M 1 829 M
P/E ratio 2020 29,6x
Yield 2020 1,66%
Sales 2021 351 B 3 358 M 3 358 M
Net income 2021 58 190 M 556 M 556 M
Net cash position 2021 224 B 2 136 M 2 136 M
P/E ratio 2021 24,7x
Yield 2021 1,79%
Capitalization 1 424 B 13 651 M 13 605 M
EV / Sales 2020 3,83x
EV / Sales 2021 3,42x
Nbr of Employees 5 267
Free-Float 45,8%
More Financials
Company
Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin Co., Ltd.) specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (94.1%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (5.9%). At the end of 2019, the group had 3... 
Sector
Pharmaceuticals
Calendar
11/03Earnings Release
More about the company
Notations Surperformance© of Kyowa Kirin Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about KYOWA KIRIN CO., LTD.
10:15aKYOWA KIRIN CO., LTD. : quaterly earnings release
10/05Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal P..
AQ
09/10MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights
AQ
08/07Japan's Kirin, hit by virus, says helped by expansion beyond beer
RE
07/30KYOWA KIRIN : Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2020 ..
PU
07/30KYOWA KIRIN : Consolidated Financial Summary (IFRS) Fiscal 2020 Interim
PU
07/30KYOWA KIRIN CO., LTD. : Half-year results
CO
07/30KYOWA KIRIN CO., LTD. : Press Release
CO
07/15Japan shares hit 5-week high on vaccine, economic growth hopes
RE
07/14Japan stocks hit 5-week high on hopes of virus drug, economic growth
RE
07/10Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio
AQ
06/29KYOWA KIRIN CO., LTD. : Ex-dividend day for interim dividend
FA
06/19Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita for the Tre..
AQ
05/15MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be highlighted ..
AQ
05/14MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b S..
AQ
More news
News in other languages on KYOWA KIRIN CO., LTD.
03:45aKYOWA KIRIN CO., LTD. : Veröffentlichung des Quartalsergebnisses
03:45aKYOWA KIRIN CO., LTD. : publication des résultats trimestriels
01/31KYOWA KIRIN CO., LTD. : Veröffentlichung des Jahresergebnisses
01/31KYOWA KIRIN CO., LTD. : publication des résultats annuels
2015Nikkei 225 : La Bourse de Tokyo finit en baisse de 0,51%
More news
Chart KYOWA KIRIN CO., LTD.
Duration : Period :
Kyowa Kirin Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KYOWA KIRIN CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 3 374,00 JPY
Last Close Price 2 651,00 JPY
Spread / Highest target 58,4%
Spread / Average Target 27,3%
Spread / Lowest Target 5,24%
EPS Revisions
Managers
NameTitle
Masashi Miyamoto President, CEO & Representative Director
Nobuo Hanai Chairman
Motohiko Kawaguchi Executive Officer, Manager-Accounting & Finance
Mitsuo Satoh Executive Officer, GM-Research & Development
Toshifumi Mikayama Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA KIRIN CO., LTD.3.03%13 754
MERCK KGAA27.91%68 876
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD114.34%20 946
BETTA PHARMACEUTICALS CO., LTD.69.71%6 490
YUHAN CORPORATION29.39%3 340
RECIPHARM AB (PUBL)9.93%1 645